10LBA Interim phase 2 results of study CO-1686-008: A phase 1/2 study of the irreversible, mutant selective, EGFR inhibitor rociletinib (CO-1686) in patients with advanced non small cell lung cancer
| Autor: | Soria, J., Sequist, L.V., Goldman, J.W., Wakelee, H.A., Gadgeel, S.M., Varga, A., Yu, H.A., Solomon, B.J., Ou, S.H., Papadimitrakopoulou, V., Oxnard, G.R., Horn, L., Dziadziuszko, R., Chao, B., Spira, A.I., Liu, S., Mekhail, T., Matheny, S., Litten, J., Camidge, R.D. |
|---|---|
| Zdroj: | In European Journal of Cancer November 2014 50 Supplement 6:199-199 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect